Glimepiride

Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. Glimepiride is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1) . Limitations of Use: Not for treating type 1 diabetes mellitus or diabetic ketoacidosis ( 1 ).

12.1 Mechanism of Action Glimepiride primarily lowers blood glucose by stimulating the release of insulin from pancreatic beta cells. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.

With Terminal t½ estimated at 10–19 hrs depending on renal/hepatic reserve (Glimepiride) residence kinetics and F ≈ 47%–59% systemic availability after standard oral Glimepiride administration bioavailability, Glimepiride undergoes mixed metabolic conjugation and unchanged urinary excretion across glimepiride regimens and establishes therapeutic activity over time to peak concentration spans 1 to 2 hrs under glimepiride maintenance.

Standard adult regimens span 1 mg/1 Tablet, 4 mg/1 Tablet, 2 mg/1 Tablet, 6 mg/1 Tablet, 3 mg/1 Tablet. Prescribers screen specifically against glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: glimepiride or any of the product’s ingredients .; sulfonamide derivatives: patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets., while community micro-logs most frequently note nausea (10.6% of reports), headache (9.2% of reports), dizziness (8.5% of reports).